Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 fostamatinib in chronic idiopathic thrombocytopenic purpura (ITP)
jRCT2080224916Phase 3Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing fostamatinib with placebo (2 arms). Primary endpoint: Platelet response in Period I. Started Oct 2019; status: completed.
02
Drugs
fostamatinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCT2080224916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224916.